我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去）

2 f- o2 q4 J+ a4 z$ J% c
( p! V; n, f8 Q1 d6 Q# J( D祝老马老师新年快乐！今天看了你的，《肺癌骨转移的双膦酸盐治疗》这篇文章，想有个问题请教你：我父亲由于手术前未确定病灶的良性还是恶性，所以先行手术，确定恶性后，手术后补做了骨扫描，结论：右侧股骨颈骨代谢增高灶，建议进一步检查。三个月后核磁复查：右侧髂骨、股骨头、股骨颈见结节状异常信号T1WI低信号、T2WI高信号。左侧股骨头见斑点状T2W1高信号影，髋臼及关节间隙如常，左侧髋关节囊见少量积液。结果诊断：右侧髂骨、股骨颈及两侧股骨头异常信号。问过好多医生，未能诊断是否骨转移。术后至今已7月多，一直未疼痛，碱性磷酸酶也正常，请问老师骨转移的可能性大吗？

我觉得骨转移可能性大，建议再做个核磁，看看有什么变化没有。
% O5 b! n- W5 s确定后可以打骨转针。
肿瘤指标有没有检查？

谢谢马老师这么快回复;肿瘤指标有检查,CEA手术前5.6,手术后2.7,总共四次培美曲塞+顺伯,前三次后CEA都在2.7左右,第四次后4.22,现在3.6,现在跟正常人一模一样,体重回升3公斤,正常上班,真想现在的好时光能长点,再长点.

LUNG CANCER HARB ORING HER2 MUTATION :EPIDE MIOLOGI CAL CHARACTE RISTICS AND
THERAPE UTIC PERSPECTIVES
J. Mazieres, S. Peters
Introduction: HER2 oncogene is a memb er of the EGFR family, encoding atransmembrane receptor that drives and regulates cell proliferation. HER2 mutations are identified in about 2% of non small cell lung cancer (NSCLC) , mainly located in exon 20, and appear to be critical for lung cancer carcinogenesis . Very scarce data are available to define a clinical profile of the patients harboring HER2 mutated NSCLC. We aimed to study clinic opatholog ical characteristics an d therapeutic
outcomes of patients harboring HER2 mutation in a large European series. Result s:We retrospec tively ide ntified 46 NSCLC patients diagn osed with HER2 exon 20 mut ation. HER2 mutation was mainly exclusive as only one concomitan t KRas mutation was des cribed. Our population was characterized by a median age of 60 yr (31 to 86 yr), a high proportion of women (30 vs. 16 men, 65% ), and of never smokers (24, 52%). All tumors were adenoc arcinomas (two with lepidic features). Half of the patients had stage IV dise ase at the time of diagnosis. HER2 targeted
treatment was delivered after convention al chemothe rapy. A total of 20 anti-Her2
3 o  {. m/ E/ A/ D: U$ ]- Xtreatments were eval uable. We observed 4 progressive dise ases, 7 disease stabilizations
and 9 partial resp onses according to RECIST 1.1 (overall response rate ORR = 45% ;
! c8 S8 q) J- P; M+ G) rdisease control rate DCR = 80%). Specifica lly, we obse rved a DCR of 92% for
, B2 ~1 H  |# N  q3 I( Otrastuzum ab-based therapie s (n = 14), 100 % for afatinib (n = 3) but no response to
0 `% p/ o. B2 N$ Hlapatinib (n = 2) and to a multiTKI (n = 1). Median survival was of 68.2 months and
4 \  H0 o& `% o8 V! B# j22.9 months for respectively early stage and stag e IV patients.
Conclusion: This study, the largest to date dedic ated to HER2 mutated NSCLC,
9 y3 J# ]) Z) w0 Q, I  `" ~reinforces the importance of an HER2 screening strategy in lung adenoc arcinomas .
HER2-target ed drugs shou ld be tested further, ide ally withi n large collaborative
4 g" {* X9 j! Jclinicaltrials.
" k' \' q  E' U- M/ F) n& f& {

老马：你好！一口气看完你的帖子，受益非浅，现在有问题想向你请教一下
   最近非常纠结于我爸爸的下一步治疗情况，想请教一下您，麻烦帮我看看他的CEA算敏感的吗？为什么最近CEA变化和肿瘤大小变化怎么不符合了呢？目前CT象征肿瘤算不算增大了呢？是否能继续空窗或者用靶向？以下是治疗帖。http://www.yuaigongwu.com/thread-8252-1-1.html

谢谢你这么快给我回复，骨转针已打了7针，是否要继续？
CEA为什么会突然变得不敏感呢？再次感谢！

5 g& f' n( D8 c4 I. Z  Z& J  B3 a

经常上来，但是第一次注册。 父也是肺鳞癌！

向老马请教，病人的淋巴细胞亚群检测是不是很重要？

; ?( P$ P; j6 e; A/ O: j$ k. m
因这个项目检查要自费
2 r; w1 w% C; O: x* P{:soso_e117:}
所以......
# m' d/ }; q2 F3 T; F下周去检查
谢谢老马！